Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Cancer Genetics India Private Limited, was an unlisted private company incorporated on 02 July, 2014. It is classified as a private subsidiary of a foreign company and is located in , Andhra Pradesh. It's authorized share capital was INR 5.00 cr and the total paid-up capital was INR 3.54 cr.
The current status of Cancer Genetics India Private Limited is - Amalgamated.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Nagabhushana Sastry Modali | 00130189 | 8 years |
Director | Bobba Venkatadri | 02272890 | 11 years |
Director | Panna Lal Sharma | 06865572 | 11 years |
Director | Raju S K Chaganti | 06949006 | 11 years |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Networth | |||||
Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
As per information available, the company has no registered charges.
Name | Status | Paid up Capital | Common Directors | Address |
---|---|---|---|---|
SINDU RESEARCH LABORATORIES PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
JAYA DIAGNOSTIC AND RESEARCH CENTRE LTD |
Active
|
7.4 Cr | 1 | Telangana |
A.P.I.D.C. VENTURE CAPITAL PRIVATE LIMITED |
Active
|
41.0 L | 1 | Telangana |
SINDU PHARMACEUTICALS PRIVATE LIMITED |
Strike Off
|
36.7 L | 1 | Telangana |
NAPO INDIA PRIVATE LIMITED |
Strike Off
|
36.3 L | 1 | Maharashtra |
RICHCORE ENZYMES PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Karnataka |
NAPO PHARMACEUTICALS INDIA PRIVATE LIMITED |
Strike Off
|
5.0 L | 1 | Maharashtra |
DIABETOMICS MEDICAL PRIVATE LIMITED |
Active
|
29.0 L | 1 | Telangana |
PATIENT FOCUS PRIVATE LIMITED |
Amalgamated
|
13.6 L | 1 | Telangana |
SPARSHA PHARMA INTERNATIONAL PRIVATE LIMITED |
Active
|
8.6 Cr | 1 | Telangana |
Read more
The incorporation date of CANCER GENETICS INDIA PRIVATE LIMITED is 02 July, 2014
The authorized share capital of CANCER GENETICS INDIA PRIVATE LIMITED is INR ₹ 5.0 Cr.
The paid-up capital of CANCER GENETICS INDIA PRIVATE LIMITED is INR ₹ 3.5 Cr.
The registered address of CANCER GENETICS INDIA PRIVATE LIMITED is PLOT NO: 65,66 & 67 JAWAHARLAL NEHRU PHARMA CITY THANAM, PARAWADA VISAKHAPATNAM Andhra Pradesh - 531019
The CIN number of CANCER GENETICS INDIA PRIVATE LIMITED is U24100AP2014FTC094746.